Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CD69 | Q07108 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20643554 | 1.00 | MAPK1 (0.49) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL22657931 | 0.87 | ALDH1A1 (0.51) | ALDH1A1ALOX15CYP1B1 | |
| SCHEMBL9791430 | 0.87 | ALDH1A1 (0.51) | ALDH1A1ALOX15CYP1B1 | |
| SCHEMBL20643561 | 0.81 | POLB (0.48) | MAPK1ALDH1A1KMT2AALOX15CYP1B1 | |
| SCHEMBL17761463 | 0.80 | ALDH1A1 (0.44) | ALDH1A1ALOX15CYP1B1 | |
| SCHEMBL542627 | 0.73 | MAPK1 (0.58) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL7150940 | 0.73 | MAPK1 (0.58) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL20643560 | 0.73 | MAPK1 (0.58) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL21097246 | 0.73 | MAPK1 (0.58) | MAPK1ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL14544300 | 0.73 | MAPK1 (0.58) | MAPK1ALDH1A1THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396823-A1 | COMPOSITIONS, METHODS AND TREATMENTS FOR INHIBITING CELL ADHESION AND VIRUS BINDING AND PENETRATION | TUMOREND, LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-11203776-B2 | Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration | TUMOREND, LLC (US) | 2021-12-21 | — | — | US | disclosed |
| US-20190017095-A1 | COMPOSITIONS, METHODS AND TREATMENTS FOR INHIBITING CELL ADHESION AND VIRUS BINDING AND PENETRATION | TUMOREND, LLC (US) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396823-A1 | COMPOSITIONS, METHODS AND TREATMENTS FOR INHIBITING CELL ADHESION AND VIRUS BINDING AND PENETRATION | SIGLEC7, SIGLEC9, HAVCR2 | MAPK1 3021/4885ALDH1A1 1675/4885THRB 2281/4885 |
| US-11203776-B2 | Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration | SIGLEC7, SIGLEC9, HAVCR2 | MAPK1 3021/4885ALDH1A1 1675/4885THRB 2281/4885 |
| US-20190017095-A1 | COMPOSITIONS, METHODS AND TREATMENTS FOR INHIBITING CELL ADHESION AND VIRUS BINDING AND PENETRATION | SIGLEC7, SIGLEC9, HAVCR2 | MAPK1 3021/4885ALDH1A1 1675/4885THRB 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.